Literature DB >> 2063958

In vitro and clinical correlates of mefloquine resistance of Plasmodium falciparum in eastern Thailand.

G E Childs1, E F Bourdeau, T Wimonwattratee, L Pang, W K Milhous.   

Abstract

A series of isolates of Plasmodium falciparum from eastern Thailand was collected prior to and after treatment failure with mefloquine. Patterns of drug sensitivity to standard and new antimalarials were characterized by using an in vitro assay based on the inhibition of schizont maturation. In vitro levels of mefloquine sensitivity of isolates were correlated with clinical treatment failures. In vitro parasite resistance to mefloquine is defined as an inhibitory dose-50 value greater than 20 nM. For isolates collected prior to treatment, there was no significant difference in mefloquine sensitivity patterns between subsequent successes and failures, suggesting that mefloquine treatment failures could not be predicted based on in vitro sensitivity of pretreatment isolates. A series of paired isolates were collected both prior to treatment with mefloquine and after recrudescence. Recrudescent isolates showed significant decreases in sensitivity to mefloquine, WR 194965, enpiroline, and halofantrine; no significant changes in sensitivity to amodiaquine, qinghaosu, and pyrimethamine; and an increase in sensitivity to chloroquine.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2063958     DOI: 10.4269/ajtmh.1991.44.553

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  6 in total

1.  Development of halofantrine resistance and determination of cross-resistance patterns in Plasmodium falciparum.

Authors:  M Nateghpour; S A Ward; R E Howells
Journal:  Antimicrob Agents Chemother       Date:  1993-11       Impact factor: 5.191

2.  High prevalence of mefloquine-resistant falciparum malaria in eastern Thailand.

Authors:  A L Fontanet; D B Johnston; A M Walker; W Rooney; K Thimasarn; D Sturchler; M Macdonald; M Hours; D F Wirth
Journal:  Bull World Health Organ       Date:  1993       Impact factor: 9.408

Review 3.  Mefloquine. A review of its antimalarial activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  K J Palmer; S M Holliday; R N Brogden
Journal:  Drugs       Date:  1993-03       Impact factor: 9.546

Review 4.  Halofantrine. A review of its antimalarial activity, pharmacokinetic properties and therapeutic potential.

Authors:  H M Bryson; K L Goa
Journal:  Drugs       Date:  1992-02       Impact factor: 9.546

5.  Antimalarial activity of WR 243251, a Dihydroacridinedione.

Authors:  J Berman; L Brown; R Miller; S L Andersen; P McGreevy; B G Schuster; W Ellis; A Ager; R Rossan
Journal:  Antimicrob Agents Chemother       Date:  1994-08       Impact factor: 5.191

Review 6.  Clinical pharmacokinetics of halofantrine.

Authors:  J Karbwang; K Na Bangchang
Journal:  Clin Pharmacokinet       Date:  1994-08       Impact factor: 6.447

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.